CA2489057A1 - Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 - Google Patents
Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 Download PDFInfo
- Publication number
- CA2489057A1 CA2489057A1 CA002489057A CA2489057A CA2489057A1 CA 2489057 A1 CA2489057 A1 CA 2489057A1 CA 002489057 A CA002489057 A CA 002489057A CA 2489057 A CA2489057 A CA 2489057A CA 2489057 A1 CA2489057 A1 CA 2489057A1
- Authority
- CA
- Canada
- Prior art keywords
- apo
- antibody
- sample
- antibodies
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Light Receiving Elements (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207542A FR2841249A1 (fr) | 2002-06-19 | 2002-06-19 | Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 |
| FR02/07542 | 2002-06-19 | ||
| PCT/FR2003/001888 WO2004000884A2 (fr) | 2002-06-19 | 2003-06-19 | Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2489057A1 true CA2489057A1 (fr) | 2003-12-31 |
Family
ID=29719858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002489057A Abandoned CA2489057A1 (fr) | 2002-06-19 | 2003-06-19 | Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050152900A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1513878B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006515561A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE356832T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003267493A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2489057A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60312513T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1513878T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2283803T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2841249A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004000884A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070207505A1 (en) * | 2004-03-29 | 2007-09-06 | Shibayagi Co., Ltd. | Method for Mesurement of Apoliporotein B-48 and its Use |
| WO2007058588A1 (en) * | 2005-11-18 | 2007-05-24 | T.A.C Thrombosis And Coagulation Aktiebolag | Monoclonal antibodies against apolipoprotein m |
| AP2008004634A0 (en) * | 2006-03-23 | 2008-10-31 | Emelta De Guzman Breyer | Apolipoprotein fingerprinting technique |
| CN104297506B (zh) | 2007-10-02 | 2017-05-03 | 赛拉诺斯股份有限公司 | 模块化现场护理装置及其应用 |
| JP5832723B2 (ja) * | 2009-03-06 | 2015-12-16 | 協和メデックス株式会社 | 可溶性インターロイキン−2受容体定量用標準品 |
| WO2010107380A1 (en) * | 2009-03-17 | 2010-09-23 | Forskarpatent I Syd Ab | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions |
| AU2010319323B2 (en) | 2009-11-14 | 2015-01-15 | Cardiovax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| US8506964B2 (en) * | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| JP2013544243A (ja) | 2010-11-12 | 2013-12-12 | シーダース シナイ メディカル センター | 動脈瘤の治療及び/又は予防のための免疫調節方法及びシステム |
| WO2012074725A2 (en) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| CN103477197B (zh) | 2011-01-21 | 2016-08-17 | 提拉诺斯公司 | 样品使用最大化的系统和方法 |
| US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
| US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
| US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
| US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
| US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
| US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
| US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
| US10401373B1 (en) | 2013-02-18 | 2019-09-03 | Theranos Ip Company, Llc | Systems and methods for analyte testing and laboratory oversight |
| US11008628B1 (en) | 2013-02-18 | 2021-05-18 | Labrador Diagnostics Llc | Systems and methods for analyte testing and laboratory oversight |
| US10422806B1 (en) | 2013-07-25 | 2019-09-24 | Theranos Ip Company, Llc | Methods for improving assays of biological samples |
| US11360107B1 (en) | 2014-02-25 | 2022-06-14 | Labrador Diagnostics Llc | Systems and methods for sample handling |
| CN106053793A (zh) * | 2016-06-20 | 2016-10-26 | 诺莱生物医学研究院(北京)有限公司 | 一种快速检测乳糜血的免疫层析试纸卡及其制备方法 |
| WO2025111449A1 (en) * | 2023-11-21 | 2025-05-30 | Sun Diagnostics, Inc. | Method and reagent to clear turbidity due to elevated triglycerides in a biological specimen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60193926A (ja) * | 1984-03-15 | 1985-10-02 | Tokyo Daigaku | 単クローン性抗ヒトアポリポ蛋白質b100抗体 |
| JPS617299A (ja) * | 1984-06-20 | 1986-01-13 | Dai Ichi Pure Chem Co Ltd | ヒトアポリポ蛋白b48に高い特異性を有する単クローン性抗体 |
| US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
-
2002
- 2002-06-19 FR FR0207542A patent/FR2841249A1/fr active Pending
-
2003
- 2003-06-19 AU AU2003267493A patent/AU2003267493A1/en not_active Abandoned
- 2003-06-19 DE DE60312513T patent/DE60312513T2/de not_active Expired - Fee Related
- 2003-06-19 CA CA002489057A patent/CA2489057A1/fr not_active Abandoned
- 2003-06-19 DK DK03748180T patent/DK1513878T3/da active
- 2003-06-19 AT AT03748180T patent/ATE356832T1/de not_active IP Right Cessation
- 2003-06-19 WO PCT/FR2003/001888 patent/WO2004000884A2/fr not_active Ceased
- 2003-06-19 ES ES03748180T patent/ES2283803T3/es not_active Expired - Lifetime
- 2003-06-19 US US10/513,916 patent/US20050152900A1/en not_active Abandoned
- 2003-06-19 JP JP2004514955A patent/JP2006515561A/ja active Pending
- 2003-06-19 EP EP03748180A patent/EP1513878B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE356832T1 (de) | 2007-04-15 |
| DK1513878T3 (da) | 2007-07-16 |
| EP1513878A2 (fr) | 2005-03-16 |
| US20050152900A1 (en) | 2005-07-14 |
| WO2004000884A3 (fr) | 2004-04-08 |
| AU2003267493A1 (en) | 2004-01-06 |
| EP1513878B1 (fr) | 2007-03-14 |
| DE60312513T2 (de) | 2007-12-06 |
| DE60312513D1 (de) | 2007-04-26 |
| JP2006515561A (ja) | 2006-06-01 |
| WO2004000884A2 (fr) | 2003-12-31 |
| ES2283803T3 (es) | 2007-11-01 |
| FR2841249A1 (fr) | 2003-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1513878B1 (fr) | Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 | |
| EP0423301A1 (fr) | Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a. | |
| WO1994004563A1 (fr) | PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS | |
| WO1990006371A1 (fr) | ANTICORPS MONOCLONAUX ANTI-INTERLEUKINES 1α ET 1β, LEUR PROCEDE DE PRODUCTION ET APPLICATIONS DESDITS ANTICORPS A LA DETECTION DES INTERLEUKINES 1α et 1β ET EN THERAPEUTIQUE | |
| EP1423707B1 (fr) | Methodes de criblage de molecules utiles pour la prevention des maladies cardiovasculaires | |
| EP2446038B1 (fr) | Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine | |
| JP3018110B2 (ja) | モノクローナル抗体 | |
| EP0327418B1 (fr) | Procédé immunométrique pour le dosage de particules de lipoprotéine, anticorps monoclonaux anti-Lp(a) et application au diagnostic de l'athérosclérose | |
| FR2709492A1 (fr) | Méthode d'immunodosage spécifique de la glutathion peroxydase plasmatique humaine, kit pour sa mise en Óoeuvre, oligopeptides et anticorps spécifiques de la méthode . | |
| Nakamura et al. | Significance of the variant and full-length forms of the very low density lipoprotein receptor in brain | |
| EP1423708B1 (fr) | Compositions et methodes pour le dosage de l'aa4rp | |
| JP2005502029A (ja) | アポbおよび非アポb含有粒子中のアポciiiを測定する新規な方法 | |
| KR0135708B1 (ko) | 인간 혈중 아포지단백질 비-100(b-100)에 대한 신규 단일클론 항체 및 이들의 생산을 위한 재조합 하이브리도마 세포주 | |
| JPH0257177A (ja) | モノクローナル抗体産生細胞ラインおよびモノクローナル抗体 | |
| JP2009263353A (ja) | 抗ラットオステオカルシンモノクローナル抗体 | |
| FR2843395A1 (fr) | Composition et methodes pour le dosage de l'aa4rp | |
| JP2000279174A (ja) | ヒトldlレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法 | |
| JP2775445B2 (ja) | 抗フェニトインモノクローナル抗体及びそれを産生するハイブリドーマ | |
| JPH0257178A (ja) | モノクローナル抗体産生細胞ラインおよびモノクローナル抗体 | |
| JP2010189381A (ja) | 抗ヒトオステオカルシンモノクローナル抗体 | |
| FR2908413A1 (fr) | Marqueur specifique d'une degradation oxydative de tissus contenant du collagene de type iii,moyens et methodes,kits de diagnostic de suivi ou de pronostic des pathologies ciblees par ce marqueur. | |
| EP0252787A1 (fr) | Polypeptides de surfaces cellulaires, isolés et purifiés, reconnus par les anticorps responsables de la pathogénie du lupus érythémateux disséminé (LED), leur méthode d'obtention et leur application au diagnostic du LED | |
| JP2011190202A (ja) | サポシンa特異的抗体及びその作成方法 | |
| JPH06135997A (ja) | イノシトール三リン酸受容体の精製法及び活性測定法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |